August 16, 2016
A UCB Inc. patent for the anti-convulsant Vimpat is valid, a Delaware federal judge said in an opinion unsealed on Monday, blocking attempts by Actavis Inc., Mylan Pharmaceuticals Inc., Apotex Inc.. and several other drugmakers to make and sell a generic versison of the drug.
January 09, 2015
The Patent Trial and Appeal Board on Friday denied a petition for inter partes review of a patent covering UCB Inc.'s epilepsy drug Vimpat, rejecting invalidity arguments by Actavis Inc. and a host of other generics makers accused of infringement.